Physician profile
Steven Long
NPI 1760446470
$2,014.68
in general payments reported to CMS, 2019-2025
15 companies · $97.96 in 2025
The $97.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $206 · 2021: $474 · 2022: $329 · 2023: $235 · 2024: $74.60 · 2025: $97.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $316.49 | 2019-2024 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $212.27 | 2020-2021 | |
| Dermira, INC. | $123.55 | 2019 | |
| Lilly USA, LLC | $119.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.44 | 2021 | |
| Allergan, INC. | $58.44 | 2020 | |
| Novo Nordisk INC | $34.54 | 2020-2024 | Wegovy |
| Exact Sciences Corporation | $23.05 | 2023 | Cologuard Collection Kit |
| Almatica Pharma LLC | $22.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.04 | 2023 | |
| Bausch Health US, LLC | $21.92 | 2022 | |
| Edwards Lifesciences Corporation | $21.69 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $16.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.